Institutional investors and hedge funds own 53.73% of the company's stock. Canadian National Railway had 61 analyst reports since July 21, 2015 according to SRatingsIntel.
A number of other research analysts have also issued reports on CP.
Canadian Pacific Railway (TSE CP) opened at C$228.23 on Friday. The company's outstanding shares are 740.27 Million. Capital Fund Management S.A. boosted its stake in shares of Canadian Pacific Railway by 217.4% in the second quarter. The Boston Common Asset Management Llc holds 27,024 shares with $4.54M value, up from 23,819 last quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp boosted its stake in shares of Canadian Pacific Railway by 31.9% in the second quarter. Scotia Capital has "Outperform" rating and $220 target.
Boston Common Asset Management Llc increased Canadian Pac Railway Ltd (CP) stake by 13.46% reported in 2017Q3 SEC filing. The stock decreased 0.23% or $0.37 during the last trading session, reaching $158.23. Finally, Goldman Sachs Group began coverage on Canadian Pacific Railway in a research report on Monday, November 13th. Sumitomo Mitsui Trust Holdings Inc. now owns 411,451 shares of the company's stock valued at $52,729,000 after buying an additional 2,971 shares in the last quarter.More news: (NYSE:UPS) Stake Boosted by Parnassus Investments CA
In taking a look at technical levels, Canadian Pacific Railway Limited (NYSE:CP) shares are trading 3.26% away from the 50 day simple moving average and 12.01% away from the 200 day simple moving average. 170,872 shares of the stock were exchanged. Peapack Gladstone Financial Corp who had been investing in Travelers Companies Inc for a number of months, seems to be less bullish one the $36.22 billion market cap company.
Canadian Pacific Railway Limited, CP from Services exhibited a market capitalization of 26.15B. The Company's drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis therapy for neurological conditions.
Canadian Pacific Railway (NYSE:CP) last released its quarterly earnings data on Wednesday, October 19th. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.26 billion. Canadian Pacific Railway's revenue was down 9.1% on a year-over-year basis.
The company was downgraded on Friday, April 21 by Loop Capital. Winch Advisory Svcs Lc invested in 0.74% or 8,019 shares. The stock of Stryker Corporation (NYSE:SYK) has "Buy" rating given on Thursday, December 15 by UBS. Canadian Pacific Railway's payout ratio is presently 17.90%. (NASDAQ:TSRO). Kistler reported 150 shares. Zacks Investment Research cut Canadian National Railway from a "hold" rating to a "sell" rating in a research note on Friday, October 27th. Vertical Research initiated coverage on shares of Canadian Pacific Railway in a report on Tuesday, October 11th. On Thursday, September 28 the stock rating was maintained by Piper Jaffray with "Buy". Canadian Pacific had 67 analyst reports since September 30, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with "Outperform" rating and $118 target in Friday, January 22 report. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the company's stock. They issued a "sell" rating and a $73.00 target price on the stock.More news: Pacers come from behind to hand Cavs another loss
Canadian National Railway Company engages in rail and related transportation business.
Looking slightly further out, the stock is 0.14% year to date. The shares were sold at an average price of $149.60, for a total transaction of $2,288,880.00. Cohen Lawrence B owns 39,102 shares. The disclosure for this sale can be found here. The quick ratio, on the other hand, is 0.4 indicating the company's current short-term liquidity.
Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid pharmaceutical products primarily in the United States. The Company's transports bulk commodities, merchandise freight, and intermodal traffic over a network of approximately 12,400 miles.More news: Sam Allardyce Left Stunned As Players "Throw In The Towel" Against Spurs